Navigation Links
Hanger Reports $0.62 Diluted EPS for the Fourth Quarter 2012

AUSTIN, Texas, Feb. 13, 2013 /PRNewswire/ -- Hanger, Inc. (NYSE: HGR) announced net sales of $272.2 million for the quarter ended December 31, 2012, an increase of $24.1 million, or 9.7%, from $248.1 million for the fourth quarter of 2011.
Diluted earnings per share were $0.62 for the fourth quarter of 2012 compared to $0.52 for the same period of 2011.  Adjusted diluted earnings per share, which excludes certain tax benefits and costs related to acquisitions, the Company's clinic management system ("Janus") and the 2010 relocation of the Company's corporate headquarters ("the relocation"), increased 16.0% to $0.58 for the fourth quarter of 2012, from $0.50 for the fourth quarter of 2011.

The $24.1 million, or 9.7%, increase in net sales for the fourth quarter of 2012 was the result of a $21.8 million, or 10.5%, increase in the Patient Care segment, comprised of a $9.8 million, or 4.7%, increase in same center sales and a $12.0 million increase from acquired entities; a $1.3 million, or 5.1%, increase in sales in the Distribution segment; and a $1.0 million, or 6.2%, increase in the Therapeutic Solutions segment.  Income from operations for the quarter ended December 31, 2012 was $38.9 million, compared to $34.3 million in the prior year.  Excluding costs related to acquisitions, Janus and the relocation, adjusted income from operations increased 13.1% to $39.8 million for the quarter ended December 31, 2012 from $35.2 million in the prior year. Adjusted income from operations as a percentage of revenue increased 40 basis points to 14.6% for the fourth quarter of 2012 compared to the same period in 2011, which was primarily attributable to the sales increase in the Patient Care segment combined with continued control of fixed costs.

Net sales increased $67.1 million, or 7.3%, to $985.6 million for the year ended December 31, 2012 from $918.5 million for 2011.  The sales increase was primarily the result of a $30.1 million, or 4.0%, increase in same center sales within the Patient Care segment and a $30.2 million increase from acquired entities, as well as a $6.8 million, or 6.8%, increase in sales in the Distribution segment.  Sales in the Therapeutic Solutions segment remained relatively flat compared to the prior year.  Adjusted income from operations increased 50 basis points as a percentage of sales from the prior year, for the same reasons discussed in the previous paragraph.  Diluted earnings per share were $1.84 for the year ended December 31, 2012, a 14.3% increase compared to $1.61 for 2011. Excluding certain tax benefits and costs related to acquisitions, Janus and the relocation, adjusted diluted earnings per share increased $0.22, or 13.8%, to $1.81 for the year ended December 31, 2012 from $1.59 for 2011.

The Company's cash flow from operations increased $19.5 million to $81.3 million for the year ended December 31, 2012 compared to $61.8 million for 2011.  As of December 31, 2012, the Company had $118.7 million in total liquidity, including $19.2 million of cash and $99.5 million available under its revolving credit facility, net of $0.5 million in letters of credit.  The Company's leverage ratio, as defined in its credit facilities, improved to 2.8 at December 31, 2012 from 3.0 at December 31, 2011.

"We reported excellent results across the board in the fourth quarter," commented Vinit K. Asar, President and Chief Executive Officer of Hanger.  "Patient Care finished the year strong with 4.7% same center sales growth and better than anticipated sales from acquisitions, Distribution reported 5.1% growth and Therapeutic Solutions reported sales growth for the first time in over a year during the fourth quarter. In 2012 our Patient Care same center sales increased 4.0%, we expanded adjusted operating margins by 50 bps, and we increased adjusted diluted earnings per share by 13.8%.  We anticipate 2013 will be another year of profitable growth, even as we continue to make key investments in capabilities aimed at enhancing long-term productivity. We are guiding to increase our adjusted diluted earnings per share between 11.6% and 15.5% for 2013."

The Company expects 2013 revenues of between $1.06 and $1.08 billion, resulting from 3% to 5% same center sales growth in its Patient Care segment, along with 3% to 5% growth in both its Distribution and Therapeutic Solutions segments. The Company anticipates adjusted diluted earnings per share between $2.02 and $2.09 for 2013, excluding approximately $0.05 for training costs related to the implementation of Janus and an increase in adjusted operating margins of between 30 to 50 basis points. The Company anticipates generating cash flow from operations of between $80 million and $100 million in 2013, and investing a total of $40 million to $50 million in capital additions.  During 2013 the Company will continue its acquisition program with a goal of closing acquisitions that total approximately $20 million in annualized revenues.

A conference call to discuss these results is scheduled to begin at 9:00 a.m. Eastern, on Thursday, February 14, 2013. Those wishing to participate should call 1-877-312-5846. In addition, a replay will be available until Thursday, February 21, 2013 by dialing 1-855-859-2056 and referencing Conference ID # 85713907.

About Hanger, Inc. – Built on the legacy of James Edward Hanger, the first amputee of the American Civil War, Hanger, Inc. (NYSE: HGR) delivers orthotic and prosthetic (O&P) patient care, distributes O&P devices and components, and provides therapeutic solutions to the broader post-acute market.  Through its Hanger Clinic business, Hanger is the largest owner and operator of O&P patient care clinics with in excess of 740 locations nationwide.  Through its subsidiary Southern Prosthetic Supply, Inc. (SPS), Hanger distributes branded and private label O&P devices, products, and components in the United States. The Company provides therapeutic solutions through its Innovative Neurotronics and Accelerated Care Plus businesses.  Steeped in over 150 years of clinical excellence and innovation, Hanger's vision is to be the partner of choice for products and services that enhance human physical capability.  For more information on Hanger, visit and follow us at,, and  

This document contains forward-looking statements relating to the Company's results of operations.  The United States Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements.  Statements relating to future results of operations in this document reflect the current views of management.  However, various risks, uncertainties and contingencies could cause actual results or performance to differ materially from those expressed in, or implied by, these statements, including the Company's ability to enter into and derive benefits from managed care contracts, the demand for the Company's orthotic and prosthetic services and products and the other factors identified in the Company's periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934.  The Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.Hanger, Inc.(in thousands, except for share and per share amounts)(Unaudited)Three Months EndedTwelve Month EndedDecember 31,December 31,Income Statement:2012201120122011Net sales

918,539Material costs

78,13671,693288,243267,677Personnel costs

89,78280,736340,971322,765Other operating expenses

55,67852,317190,554178,335Relocation expenses

-495-1,185Acquisition expenses

4804121,171781Depreciation and amortization

9,2208,11734,65230,969Income from operations

38,90634,318129,959116,827Interest expense

7,9587,85531,16931,821Income before taxes

30,94826,46398,79085,006Provision for income taxes

9,1648,50034,72129,987Net income

55,019Basic Per Common  Share Data:Net income

.64Shares used to compute basic per share amounts

34,453,08433,745,39734,282,59133,544,813Diluted Per Common Share Data:Net income 

.61Shares used to compute diluted per share amounts

34,945,54734,260,03034,832,83034,220,256Reconciliation of GAAP financial measures to Non-GAAP financial measures:Income from operations

,827Relocation expenses

-495-1,185Acquisition expenses

4804121,171781Janus expenses

438-533-Adjusted Income from operations

8,793Net income 

55,019Relocation expenses

-495-1,185Acquisition expenses

4804121,171781Janus expenses

438-533-Tax effect of adjustments

(344)(354)(638)(767)Non-recurring tax benefits

(2,080)(1,320)(2,080)(1,780)Adjusted net income 

54,438Adjusted net income per diluted share

.59Three Months EndedTwelve Month EndedDecember 31,December 31,Income Statement as a % of Net Sales:2012201120122011Net sales

100.0%100.0%100.0%100.0%Material costs

28.7%28.9%29.2%29.1%Personnel costs

33.0%32.5%34.6%35.1%Other operating expenses

20.4%21.1%19.4%19.4%Relocation expenses

0.0%0.2%0.0%0.1%Acquisition expenses

0.2%0.2%0.1%0.1%Depreciation and amortization

3.5%3.3%3.5%3.4%Income from operations

14.2%13.8%13.2%12.8%Interest expense

2.9%3.2%3.2%3.5%Income before taxes

11.3%10.6%10.0%9.3%Provision for income taxes

3.3%3.4%3.5%3.3%Net income 

8.0%7.2%6.5%6.0%Adjusted income from operations

14.6%14.2%13.4%12.9%Adjusted net income

7.4%6.9%6.4%5.9%Hanger, Inc.( in thousands, except for statistical data)(Unaudited)Three Months EndedTwelve Months EndedDecember 31,December 31,Cash Flow Data:2012201120122011Cash flow provided by operations 

$  22,312$ 24,654$   81,319$
,804Capital expenditures

7,429$   6,370$   32,306$
28,674Increase/(decrease) in cash and cash equivalents

$(36,409)$ 11,459$ (23,685)$
,588Balance Sheet Data:December 31, 2012December 31, 2011Cash and cash equivalents$   19,211$
42,896Days Sales Outstanding (DSO's)5854Working Capital $ 252,923$  241,729Total Debt$ 520,646$  508,033Shareholders' Equity$ 504,552$  429,664Three Months EndedTwelve Months EndedDecember 31,December 31,2012201120122011Revenue Mix:Patient Care


9.6%10.1%10.9%10.9%Therapeutic solutions

6.2%6.3%6.6%7.0%Patient Care Payor Mix:Commercial and other




6.0%5.7%6.1%5.5%Management relies on the non-GAAP items as the primary measures to review and assess operating performance and management teams. The Company believes it is useful to investors to provide disclosures of its operating results on the same basis as that used by management.  Management and investors also review the non-GAAP items to evaluate the Company's overall performance and to compare its current operating results with corresponding periods and with other companies in the health care industry. You should not consider the non-GAAP items in isolation or as a substitute for net income, operating cash flows or other cash flow statement data determined in accordance with accounting principles generally accepted in the United States. Because the non-GAAP items are not measures of financial performance under accounting principles generally accepted in the United States and are susceptible to varying calculations, they may not be comparable to similarly titled measures of other companies.  Adjusted net income, Adjusted income from operations, and Adjusted net income per diluted share are the non-GAAP financial measures.

SOURCE Hanger Orthopedic Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hanger, Inc. Has Record Year In O&P Acquisitions:
2. Hanger Reports Earnings of $0.50 Per Diluted Share for the Third Quarter 2012
3. Hanger, Inc. Announces 2012 Year To Date Acquisitions Totaling $35.6 Million Of Annual Net Revenue
4. Hanger, Inc. Reports Earnings of $0.50 Per Diluted Share for the Second Quarter 2012
5. Hanger, Inc. Announces Second Quarter 2012 Earnings Release Conference Call
6. Hanger Orthopedic Group, Inc. announces name change to Hanger, Inc.
7. Hanger clinicians honored with 2012 Tribeca Disruptive Innovation Award
8. Hospira Reports Fourth-Quarter and Full-Year 2012 Results
9. Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
10. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
11. Landauer, Inc. Reports Fiscal 2013 First Quarter Results
Post Your Comments:
(Date:10/9/2015)... 9, 2015  Hi-Tech Pharmaceuticals ("Hi-Tech"), a leading ... and iForce Nutrition ("iForce"), one of the fastest-growing Sports ... , today announced that they have entered ... agreed to acquire iForce. The transaction will enhance ... distribution through iForce,s strong distribution network. ...
(Date:10/9/2015)... 2015 Adheron Therapeutics, a privately held ... , United States , ... acquired by Roche.  Adheron Therapeutics has developed a ... a cell surface protein called Cadherin-11 in order ... inflammatory and autoimmune diseases such as rheumatoid arthritis ...
(Date:10/9/2015)... October 9, 2015 El ,JCA-Mauvernay Award 2015, ... y Junko Takita    --> ... los doctores Yutaka Kondo y ... Award 2015, se ha otorgado a los doctores ... ™ , una compañía biofarmacéutica global con sede enSuiza, presentará el ...
Breaking Medicine Technology:
... (Nasdaq: INSM ), a biopharmaceutical company, announced ... Agency (EMA) has issued a positive opinion on the ... for inhalation), Insmed,s Phase 3-ready compound for cystic fibrosis ... infections.  The PIP covers children from birth to 18 ...
... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA ... announced today it submitted the application to commence clinical ... China,s State Food and Drug Administration (SFDA) on March ... research program in 2008. The vaccine targets infants under ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... The sixth annual cost ... the growth of cybercrime costs for US companies. The New York Times broke down ... With averages showing increases hovering around 20% among the companies surveyed, it only proves ...
(Date:10/10/2015)... ... October 10, 2015 , ... Story Chaser ... It works by reading various classics and inspiring stories and as words drop down ... , The animations are extremely aesthetic and can be interacted with, making it a ...
(Date:10/10/2015)... ... ... Isabel Healthcare will participate in the Cerner Health Conference October 11-14, 2015 ... Institute of Medicine’s latest report “Improving Diagnosis in Healthcare”, Isabel Healthcare will be featuring ... and consumers to potentially reduce the chance of error. The report suggests that most ...
(Date:10/10/2015)... FLA. (PRWEB) , ... October 10, 2015 , ... In ... has been named the Best Place To Work in Jacksonville, amongst medium-sized companies with ... September 27th and was followed up with a celebratory gala on October 1st. ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American ... Dean for Graduate Medical Education J. Michael Finley, DO, as the recipient of ... selected for his impact on graduate medical education opportunities for osteopathic residents, and ...
Breaking Medicine News(10 mins):
... flu outbreak in February in India, the poultry market saw a ... the government assured the people that all the necessary measures are ... the avian flu the sales of chicken and other birds saw ... deaths due to bird flu the sales dips drastically. Every time ...
... of cognitive behavior therapy (CBT) in overcoming depression can ... the University of Pittsburgh School of Medicine. In a ... Journal of Psychiatry, the official journal of the American ... the response to therapy could be a valuable tool ...
... who suffer from severe urinary infection are more likely ... had found a link between acute infections and heart ... infections and clotting in large veins, reported the online ... at the London School of Hygiene and Tropical Medicine ...
... new genes found with breast tumors can predict the outcomes ... the report appearing in he April 1 issue of Clinical ... women at risk for an early relapse of breast cancer. ... discovered as a potential marker of relapse in hormone-receptor positive ...
... from Sheffield University most women still believe one-night stands ... revealed that women of all ages believe that sex ... ,The women community despite achieving liberation still feels ... of desperation or drunkenness. The research which was followed ...
... are still left confused despite making in-depth analysis in ... psychiatric problem that affects the children. ... which is beyond the scientists' control, between 30 percent ... co-existing conditions, so-called comorbidities that make diagnosis and treatment ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: